Finanzen von PharmaCyte Biotech Inc (PMCB)PMCBPharmaCyte Biotech Inc

Evaluating the bottom line, PharmaCyte Biotech Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -54.22%, provide a clear picture of how effectively PMCB converts its operational activities into shareholder value.

In the context of the broader market, PMCB competes directly with industry leaders such as YCBD and ENVB. With a market capitalization of $5.92M, it holds a significant position in the sector. When comparing efficiency, PMCB's gross margin of N/A stands against YCBD's 53.29% and ENVB's N/A. Such benchmarking helps identify whether PharmaCyte Biotech Inc is trading at a premium or discount relative to its financial performance.

The company has reported significant losses, with a net income of -$8,410,610 in Q2 2026 and a forward P/E of 7.0175, which is not favorable for a growth stock. The current ratio is exceptionally high at 45.28, indicating strong liquidity, but this does not offset the ongoing losses.